Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 77-84

  Mahalingam, Devalingam ^a   Malik, Laeeq ^a   Beeram, Muralidhar ^a   Rodon, Jordi ^a   Sankhala, Kamalesh ^a   Mita, Alain ^a   Benjamin, Daniel ^a   Ketchum, Norma ^a   Michalek, Joel ^a   Tolcher, Anthony ^a   Wright, John ^b   Sarantopoulos, John ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Melanoma; Sorafenib; VEGF

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CORRELATION ANALYSIS; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; FEMALE; HAND FOOT SYNDROME; HEMOPTYSIS; HICCUP; HOARSENESS; HUMAN; HYPERTENSION; HYPOKALEMIA; LEG CRAMP; MALE; METASTATIC MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DRUG MONITORING; EARLY TERMINATION OF CLINICAL TRIALS; FEASIBILITY STUDIES; FEMALE; HAND-FOOT SYNDROME; HUMANS; HYPERTENSION; KINETICS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84903818179     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2479-8     Document Type: Article

References (27)

1. Jemal A, Saraiya M, Patel P, Cherala S, Barnholtz-Sloan J, Kim J, Wiggins C, Wingo P (2011) Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 65(5 Suppl 1):S17-25 e11-13. doi:10.1016/j.jaad.2011.04.032
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30. doi:10.3322/caac.21166
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206. doi:10.1200/ jco.2009.23.4799
4. Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18(22):3782-3793
5. Pisacane AM, Risio M (2005) VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res 15(1):39-43 (Pubitemid 40354472)
6. Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3(6):411-421. doi:10.1038/nrc1092 (Pubitemid 37328845)
7. Folberg R, Hendrix MJ, Maniotis AJ (2000) Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156(2):361-381. doi:10.1016/s0002-9440(10)64739-6 (Pubitemid 30648785)
8. Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, Gupta TK, Folberg R (2001) Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 7(3):473-477 (Pubitemid 32707967)
9. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577-583 (Pubitemid 32112873)
10. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593-4599 (Pubitemid 27441066)
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai A, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 356(2):125-134. doi:10.1056/NEJMoa060655 (Pubitemid 46089673)
12. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26(22):3709-3714. doi:10.1200/jco.2007.10.8332
13. Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC (2010) Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 102(3):495-499. doi:10.1038/sj.bjc.6605514
14. Sosman J, Flaherty K, Atkins M, Puzanov I, McDermott D, Vermeulen W, Harlacker K, Hsu A, Rothenberg M (2006) A phase I/II trial of Sorafenib with Bevacizumab in metastatic renal cell cancer patients. J Clin Oncol 24:(Abstr 3031)
15. Galanis E, Jaeckle KA, Anderson S, Kaufmann T, Uhm JH, Giannini C, Kumar S, Northfelt D, Flynn P, Buckner J (2010) NCCTG phase II trial of Bevacizumab in combination with Sorafenib in recurrent GBM. J Clin Oncol 28:(abstr 2018)
16. Grothey A, Lafky J, Morlan B, Stella P, Dakhil S, Steen P, Loui W, Bot B, Alberts S, Reynolds J (2010) Dual VEGF inhibition with Sorafenib and Bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C. J Clin Oncol 28:(abstr 3549)
17. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A, Bundred NJ (2000) Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 92(16):1329-1336 (Pubitemid 30660593)
18. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24. doi:10.1200/jco.2005.02.2574 (Pubitemid 46630489)
19. Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15(5):1612-1622. doi:10.1158/1078-0432.ccr-08-2057
20. Longo R, Gasparini G (2007) Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 60(2):151- 170. doi:10.1007/s00280-006- 0403-6
21. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516. doi: 10.1056/NEJMoa1103782
22. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE III, O'Day SJ (2012) BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30(1):34-41. doi:10.1200/jco.2011.34. 6270
23. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX, Walker MJ, Carson WE III (2007) A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14(8):2367-2376. doi:10.1245/ s10434-007-9389-5
24. Denduluri N, Yang SX, Berman AW, Nguyen D, Liewehr DJ, Steinberg SM, Swain SM (2008) Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 7(1):15-20 (Pubitemid 351590445)
25. Leighl N, Reck M, Haas S, Evers S, Delmar P, Manegold C, Scherer S (2009) 9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC). Eur J Cancer 7(2):558
26. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19(4):929-937. doi:10.1158/1078-0432.ccr-12-2535
27. Si L, Han M, Chi Z, Cui C, Sheng X, Li S, Kong Y, Guo J (2010) Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma. J Clin Oncol 28(15s):(abstr 8564)